Gastrointestinal

Mesoblast Acquires Mayo Clinic’s Chimeric Antigen Receptor (CAR) Platform to Enhance its Stem Cell Therapies

Mesoblast has secured exclusive global rights to a CAR technology platform to engineer its MSC therapies for more precise targeting and greater potency in inflammatory and autoimmune diseases, including bowel disease and...

Business, Gastrointestinal | April 26, 2026

NeuroScientific Appoints Dr. Cathy Cole to Lead Stem Cell Therapy Development for Crohn’s Disease

NeuroScientific brings Dr. Cole onboard as it advances stem cell research and prepares for clinical trials.

Gastrointestinal, Immunology | July 27, 2025

L2 Bio looking for Principal Investigators for its Phase 2B adipose stem cell trial for Crohn’s Disease

The FDA has recently approved them for what appears to be an expanded adipose MSC trial, looking for GI experienced physicians.

Gastrointestinal | June 18, 2025